ESTIMATED
05/09/2024
05/09/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $0.20 | $0.20 | $0.20 |
Q2 2024 | 5 | $0.13 | $0.18 | $0.16 |
Q3 2024 | 1 | $0.16 | $0.16 | $0.16 |
Q4 2024 | 1 | $0.21 | $0.21 | $0.21 |
Q1 2025 | 2 | $0.11 | $0.11 | $0.11 |
Q2 2025 | 2 | $0.17 | $0.17 | $0.17 |
Q3 2025 | 2 | $0.21 | $0.21 | $0.21 |
Q4 2025 | 2 | $0.26 | $0.26 | $0.26 |
Ironwood Pharmaceuticals, Inc. last posted its earnings results on Thursday, May 9th, 2024. The company reported $-0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by $0.2. The company had revenue of 74.88 M for the quarter and had revenue of 442.74 M for the year. Ironwood Pharmaceuticals, Inc. has generated $-6 earnings per share over the last year ($-6.45 diluted earnings per share) and currently has a price-to-earnings ratio of -0.96. Ironwood Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/09/2024 | Q1 2024 | $0.18 | -$0.03 | -0.21 | $105.75 M | $74.88 M | 02/16/2024 | Q4 2023 | -$0.01 | $117.47 M | $117.55 M | 11/09/2023 | Q3 2023 | $0.16 | $0.10 | -0.06 | $113.74 M | 08/09/2023 | Q2 2023 | -$6.84 | $107.38 M | 05/04/2023 | Q1 2023 | $0.24 | $0.30 | 0.06 | $100.35 M | $104.06 M | 02/16/2023 | Q4 2022 | $0.27 | $0.32 | 0.05 | $108.04 M | $107.20 M | 11/03/2022 | Q3 2022 | $0.27 | $0.28 | 0.01 | $108.64 M | 08/04/2022 | Q2 2022 | $0.30 | $0.24 | -0.06 | $97.23 M | 05/05/2022 | Q1 2022 | $0.26 | $0.21 | -0.05 | $97.53 M | 02/17/2022 | Q4 2021 | $0.25 | $110.18 M | $117.13 M | 11/04/2021 | Q3 2021 | $0.31 | $0.34 | 0.03 | $105.28 M | $103.75 M | 08/05/2021 | Q2 2021 | $0.23 | $2.42 | 2.19 | $93.85 M | $104.03 M | 05/06/2021 | Q1 2021 | $0.21 | $0.25 | 0.04 | $88.85 M | 02/17/2021 | Q4 2020 | $0.27 | $0.27 | 0 | $111.95 M | $116.68 M | 11/05/2020 | Q3 2020 | $0.15 | $0.22 | 0.07 | $93.10 M | $103.47 M | 08/06/2020 | Q2 2020 | $0.09 | $0.16 | 0.07 | $84.76 M | $89.43 M | 05/06/2020 | Q1 2020 | $0.11 | $0.02 | -0.09 | $79.94 M | 02/13/2020 | Q4 2019 | $0.24 | $0.31 | 0.07 | $112.03 M | $126.30 M | 10/31/2019 | Q3 2019 | $0.10 | $0.13 | 0.03 | $97.16 M | $131.17 M | 07/30/2019 | Q2 2019 | $0.02 | $0.08 | 0.06 | $89.29 M | $102.22 M |
---|
A. Ironwood Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. The conference call for Ironwood Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Ironwood Pharmaceuticals, Inc.'s latest earnings report can be read online.
A. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has a recorded annual revenue of $442.74 M.
A. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has a recorded net income of $442.74 M. Ironwood Pharmaceuticals, Inc. has generated $-6.45 earnings per share over the last four quarters.
A. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has a price-to-earnings ratio of -0.96 and price/earnings-to-growth ratio is -0.91.